Daratumumab vs Isatuximab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Myeloma

Shared mechanism: CD38 · full Multiple Myeloma pipeline

Daratumumab

Marketed by Johnson & Johnson

Approved in Multiple Myelomamonoclonal antibody
Partial signal

NCT02076009 · Phase 3 · completed

This open-label, randomized Phase 3 trial (POLLUX) assigned 569 patients with relapsed or refractory multiple myeloma to lenalidomide and dexamethasone with or without daratumumab. The primary endpoint was progression-free survival. At the protocol-specified interim analysis, daratumumab significantly lowered the risk of progression or death (hazard ratio 0.37, 95% CI 0.27 to 0.52, P<0.001), so the primary was met. Source: the peer-reviewed paper (Dimopoulos et al., N Engl J Med 2016).

Next expected readout: November 2026 · NCT04973605 (registry estimate)

Reported efficacy

Percentage of Participants Who Had Minimal Residual Disease (MRD) Conversion From Baseline to 12 Months After Start of Maintenance Treatment as Determined by Next Generation Sequencing (NGS) (From randomization up to 12 months): Percentage of Participants Who Had Minimal Residual Disease (MRD) Conversion From Baseline to 12 Months After Start of Maintenance Treatment as Determined by Next Generation Sequencing (NGS) (From randomization up to 12 months): Daratumumab + Lenalidomide 50.5% (95% CI 40.3 to 60.7) vs Lenalidomide 18.8% (95% CI 11.7 to 27.8) (met)

Result source: NCT03901963

Isatuximab

Marketed by Sanofi

Approved in Multiple Myelomamonoclonal antibody
Partial signal

NCT02990338 · Phase 3 · completed

Participants were randomized 1:1 to isatuximab plus pomalidomide and dexamethasone or pomalidomide and dexamethasone alone, but the study was open-label rather than double-blind. The primary clinical endpoint, progression-free survival, was met: median survival was 11.53 versus 6.47 months, with a hazard ratio of 0.596 and p=0.0005.

Next expected readout: November 2026 · NCT06517017 (registry estimate)

Reported efficacy

Progression Free Survival (PFS) (From the date of randomization to the date of first documentation of progression, or the date of death from any cause, or initiation of further anti-myeloma treatment or data cut-off whichever comes first (maximum duration: 76.7 weeks)): Progression Free Survival (PFS) (From the date of randomization to the date of first documentation of progression, or the date of death from any cause, or initiation of further anti-myeloma treatment or data cut-off whichever comes first (maximum duration: 76.7 weeks)): IPd (Isatuximab + Pomalidomide + Dexamethasone) 11.53 months (95% CI 8.936 to 13.897) vs Pd (Pomalidomide + Dexamethasone) 6.47 months (95% CI 4.468 to 8.279) (met)

Result source: NCT02990338

Results for Multiple Myeloma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDaratumumabIsatuximab
PFS, median46.7bn 444NCT02541383
15 other results
11.5 vs 6.5vs Pomalidomide + Dexamethasonen 154NCT02990338
7 other results
OS, median67.6 vs 51.8vs Lenalidomide, Low-dose Dexamethasonen 153NCT02076009
13 other results
24.6 vs 17.7vs Pomalidomide + Dexamethasonen 154NCT02990338
1 other result
ORR43.3% vs 39.4%vs Daratumumab IVn 263NCT03277105
28 other results
60.4% vs 35.3%vs Pomalidomide + Dexamethasonen 154NCT02990338
7 other results
VGPR or better75.8% vs 44.2%vs Lenalidomide, Low-dose Dexamethasonen 281NCT02076009
8 other results
31.8% vs 8.5%vs Pomalidomide + Dexamethasonen 154NCT02990338
1 other result
  • 72.6% vs 56.1% n 179 · Phase 3 · secondary NCT03275285
MRD negativity53.3% vs 35.4%vs Bortezomib-lenalidomide-dexamethasone (VRd)n 197NCT03652064
8 other results
—Not posted · NCT05804032

PFS, median

Daratumumab
46.7bn 444NCT02541383
15 other results
Isatuximab
11.5 vs 6.5vs Pomalidomide + Dexamethasonen 154NCT02990338
7 other results

OS, median

Daratumumab
67.6 vs 51.8vs Lenalidomide, Low-dose Dexamethasonen 153NCT02076009
13 other results
Isatuximab
24.6 vs 17.7vs Pomalidomide + Dexamethasonen 154NCT02990338
1 other result

ORR

Daratumumab
43.3% vs 39.4%vs Daratumumab IVn 263NCT03277105
28 other results
Isatuximab
60.4% vs 35.3%vs Pomalidomide + Dexamethasonen 154NCT02990338
7 other results

VGPR or better

Daratumumab
75.8% vs 44.2%vs Lenalidomide, Low-dose Dexamethasonen 281NCT02076009
8 other results
Isatuximab
31.8% vs 8.5%vs Pomalidomide + Dexamethasonen 154NCT02990338
1 other result
  • 72.6% vs 56.1% n 179 · Phase 3 · secondary NCT03275285

MRD negativity

Daratumumab
53.3% vs 35.4%vs Bortezomib-lenalidomide-dexamethasone (VRd)n 197NCT03652064
8 other results
Isatuximab
—Not posted · NCT05804032
  1. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
13 other shared endpoints and safety

Coverage. Daratumumab: 17 of 17 rows · Isatuximab: 17 of 17 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricDaratumumab
Rows use multiple source trials
Isatuximab
Rows use multiple source trials
Clinical Benefit
responder rate · % of participants
No placebo or comparator arm
34% (n=106)16 mg/kga,b,c,d
NCT01985126 · Phase 2
show 1 more dose
22.2% (n=18)8 mg/kg
NCT01985126 · Phase 2
23.5% (n=34)a,b,c,d
NCT03194867 · Phase 1/2 · registry result, not featured evidence
show 2 more doses
36.1% (n=36)
NCT03194867 · Phase 1/2 · registry result, not featured evidence · combination
38.9% (n=36)
NCT03194867 · Phase 1/2 · registry result, not featured evidence · combination
Complete
responder rate · % of participants
28.5% (n=312) vs 10.4% (n=154) Carfilzomib and Dexamethasonec,d
NCT03158688 · Phase 3 · registry result, not featured evidence · combination
44.1% (n=179) vs 28.5% (n=123) Carfilzomib + Dexamethasonec,d
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
Complete Response With MRD Negativity
responder rate · % of participants
12.8% (n=312) vs 1.9% (n=154) Carfilzomib and Dexamethasone @ 52wkc,d
NCT03158688 · Phase 3 · registry result, not featured evidence · combination
26.3% (n=179) vs 12.2% (n=123) Carfilzomib + Dexamethasonec,d
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
Duration of Response
time to event · months
NA vs 17.4 Lenalidomide, Low-dose Dexamethasone monthsd
NCT02076009 · Phase 3 · combination · Multiple Myeloma · phase 3
5 other source trials
NA vs 43.7 Lenalidomide + Dexamethasone months
NCT02252172 · Phase 3 · registry result, not featured evidence · combination
NA vs 21.3 Velcade, Melphalan and Prednisone months
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
10.15 vs 10.64 Daratumumab IV months
NCT03277105 · Phase 3 · registry result, not featured evidence
NA vs 16.6 Carfilzomib and Dexamethasone months
NCT03158688 · Phase 3 · registry result, not featured evidence · combination
NA vs NA Lenalidomide+Bortezomib+Dexamethasone months
NCT02874742 · Phase 2 · registry result, not featured evidence · combination
13.27 vs 11.07 Pomalidomide + Dexamethasone monthsd
NCT02990338 · Phase 3 · combination · Multiple Myeloma · phase 3
1 other source trial
NA vs NA Carfilzomib + Dexamethasone months
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
Duration of Response
time to event · months
No placebo or comparator arm
7.4 months16 mg/kga,b,c,d
NCT01985126 · Phase 2
show 1 more dose
NA months8 mg/kg
NCT01985126 · Phase 2
5.6 monthsa,b,c,d
NCT03194867 · Phase 1/2 · registry result, not featured evidence
show 2 more doses
4.7 months
NCT03194867 · Phase 1/2 · registry result, not featured evidence · combination
5.7 months
NCT03194867 · Phase 1/2 · registry result, not featured evidence · combination
ORR
responder rate · % of participants
No placebo or comparator arm
29.2% (n=106)16 mg/kga,b,c,d
NCT01985126 · Phase 2
show 1 more dose
11.1% (n=18)8 mg/kg
NCT01985126 · Phase 2
11.8% (n=34)a,b,c,d
NCT03194867 · Phase 1/2 · registry result, not featured evidence
show 2 more doses
25% (n=36)
NCT03194867 · Phase 1/2 · registry result, not featured evidence · combination
22.2% (n=36)
NCT03194867 · Phase 1/2 · registry result, not featured evidence · combination
Overall Survival
time to event · months
No placebo or comparator arm
18.6 months16 mg/kga,b,c,d
NCT01985126 · Phase 2
show 1 more dose
19.45 months8 mg/kg
NCT01985126 · Phase 2
NA monthsa,b,c,d
NCT03194867 · Phase 1/2 · registry result, not featured evidence
show 2 more doses
NA months
NCT03194867 · Phase 1/2 · registry result, not featured evidence · combination
12.78 months
NCT03194867 · Phase 1/2 · registry result, not featured evidence · combination
PFS
time to event · months
No placebo or comparator arm
3.65 months16 mg/kga,b,c,d
NCT01985126 · Phase 2
show 1 more dose
4.86 months8 mg/kg
NCT01985126 · Phase 2
2.89 monthsa,b,c,d
NCT03194867 · Phase 1/2 · registry result, not featured evidence
show 2 more doses
3.75 months
NCT03194867 · Phase 1/2 · registry result, not featured evidence · combination
3.02 months
NCT03194867 · Phase 1/2 · registry result, not featured evidence · combination
PFS2
time to event · months
73.72 vs 48.89 Lenalidomide + Dexamethasone monthsc,d
NCT02252172 · Phase 3 · registry result, not featured evidence · combination
1 other source trial
66.73 vs 42.41 Velcade, Melphalan and Prednisone months
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
47.18 vs 35.58 Carfilzomib + Dexamethasone monthsa,c,d
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
show 1 more dose
47.18 vs 32.36 Carfilzomib + Dexamethasone months
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
Time to Progression
time to event · months
NA vs 18.43 Lenalidomide, Low-dose Dexamethasone monthsd
NCT02076009 · Phase 3 · combination · Multiple Myeloma · phase 3
5 other source trials
NA vs 7.29 Bortezomib + Dexamethasone months
NCT02136134 · Phase 3 · combination · Multiple Myeloma · phase 3
NA vs 40.87 Lenalidomide + Dexamethasone months
NCT02252172 · Phase 3 · registry result, not featured evidence · combination
NA vs 19.35 Velcade, Melphalan and Prednisone months
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
NA vs 17.5 Carfilzomib and Dexamethasone months
NCT03158688 · Phase 3 · registry result, not featured evidence · combination
NA vs NA Lenalidomide+Bortezomib+Dexamethasone months
NCT02874742 · Phase 2 · registry result, not featured evidence · combination
12.71 vs 7.75 Pomalidomide + Dexamethasone monthsd
NCT02990338 · Phase 3 · combination · Multiple Myeloma · phase 3
1 other source trial
NA vs 20.27 Carfilzomib + Dexamethasone months
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
Time to Progression
time to event · months
No placebo or comparator arm
3.71 months16 mg/kga,b,c,e,d
NCT01985126 · Phase 2
show 1 more dose
4.86 months8 mg/kg
NCT01985126 · Phase 2
5.5 months20 mg/kgb,c,e,d
NCT02812706 · Phase 1/2 · registry result, not featured evidence
Time to Response
time to event · months
1 vs 1.3 Lenalidomide, Low-dose Dexamethasone monthsd
NCT02076009 · Phase 3 · combination · Multiple Myeloma · phase 3
4 other source trials
0.79 vs 0.82 Velcade, Melphalan and Prednisone months
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
1.02 vs 1.02 Daratumumab IV months
NCT03277105 · Phase 3 · registry result, not featured evidence
1.4 vs 1.5 Carfilzomib and Dexamethasone months
NCT03158688 · Phase 3 · registry result, not featured evidence · combination
0.8 vs 0.8 Lenalidomide+Bortezomib+Dexamethasone months
NCT02874742 · Phase 2 · registry result, not featured evidence · combination
1.94 vs 3.02 Pomalidomide + Dexamethasone monthsd
NCT02990338 · Phase 3 · combination · Multiple Myeloma · phase 3
Time to Response
time to event · months
No placebo or comparator arm
0.99 months16 mg/kga,b,c,d
NCT01985126 · Phase 2
show 1 more dose
0.99 months8 mg/kg
NCT01985126 · Phase 2
1.5 monthsa,b,c,d
NCT03194867 · Phase 1/2 · registry result, not featured evidence
show 2 more doses
1 months
NCT03194867 · Phase 1/2 · registry result, not featured evidence · combination
1 months
NCT03194867 · Phase 1/2 · registry result, not featured evidence · combination
Dropout rate
n/a: no completion milestonef
NCT02076009 · Phase 3 · combination · Multiple Myeloma · phase 3
show 54 more results
n/a: no completion milestone
NCT02136134 · Phase 3 · combination · Multiple Myeloma · phase 3
n/a: no completion milestone
NCT03301220 · Phase 3 · combination · Multiple Myeloma · phase 3
94.9%
NCT03901963 · Phase 3 · combination
n/a: no completion milestone16 mg/kg
NCT01985126 · Phase 2
n/a: no completion milestone8 mg/kg
NCT01985126 · Phase 2
66.7%24 mg/kg
NCT00574288 · Phase 2
66.7%16 mg/kg
NCT00574288 · Phase 2
66.7%16 mg/kg
NCT00574288 · Phase 2
100%8 mg/kg
NCT00574288 · Phase 2
86.7%8 mg/kg
NCT00574288 · Phase 2
100%4 mg/kg
NCT00574288 · Phase 2
100%<4 mg/kg
NCT00574288 · Phase 2
10%
NCT05511428 · Phase 4 · registry result, not featured evidence
n/a: no completion milestone
NCT03652064 · Phase 3 · registry result, not featured evidence
—Daratumumab (IV)+Pomalidomide+Dexa
NCT03180736 · Phase 3 · registry result, not featured evidence · combination
—Daratumumab (SC)+Pomalidomide+Dexa
NCT03180736 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT02252172 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT03277105 · Phase 3 · registry result, not featured evidence
—DVTd - Part 1
NCT02541383 · Phase 3 · registry result, not featured evidence · combination
—DVTd-DARA - Part 2
NCT02541383 · Phase 3 · registry result, not featured evidence
—VTd-DARA - Part 2
NCT02541383 · Phase 3 · registry result, not featured evidence
67.3%
NCT03158688 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT03357952 · Phase 2/3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 2/3
0%
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
6.1%
NCT03477539 · Phase 2 · registry result, not featured evidence
97.6%Arm A (Long Intense)
NCT02316106 · Phase 2 · registry result, not featured evidence
100%Arm B (Intermediate)
NCT02316106 · Phase 2 · registry result, not featured evidence
100%Arm C (Short Intense)
NCT02316106 · Phase 2 · registry result, not featured evidence
71.6%D + Bortezomib + Melphalan + Predn
NCT03412565 · Phase 2 · registry result, not featured evidence · combination
1.5%Daratumumab (D)+Bortezomib+Lenalid
NCT03412565 · Phase 2 · registry result, not featured evidence · combination
77.3%Daratumumab + Carfilzomib + Dexame
NCT03412565 · Phase 2 · registry result, not featured evidence · combination
78.5%Daratumumab + Lenalidomide + Dexam
NCT03412565 · Phase 2 · registry result, not featured evidence · combination
0%
NCT03490344 · Phase 2 · registry result, not featured evidence
15.4%
NCT02874742 · Phase 2 · registry result, not featured evidence · combination
60.5%
NCT03450057 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT03000452 · Phase 2 · registry result, not featured evidence · combination
0%
NCT02944565 · Phase 2 · registry result, not featured evidence
33.3%16 mg/kg
NCT01615029 · Phase 1/2 · registry result, not featured evidence · combination
50%16 mg/kg
NCT01615029 · Phase 1/2 · registry result, not featured evidence · combination
100%8mg/kg
NCT01615029 · Phase 1/2 · registry result, not featured evidence · combination
33.3%4 mg/kg
NCT01615029 · Phase 1/2 · registry result, not featured evidence · combination
66.7%2 mg/kg
NCT01615029 · Phase 1/2 · registry result, not featured evidence · combination
—Nivolumab + Daratumumab Cohort A1
NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination
83.3%Nivolumab + Daratumumab_Cohort A1
NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination
85.7%Nivolumab + Daratumumab_Cohort A2
NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination
83.7%Nivolumab + Daratumumab_Cohort B1
NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination
72.7%Nivolumab + Daratumumab_Cohort B2
NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination
38.5%Nivolumab + Ipilimumab
NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination
100%Nivolumab + Lirilumab
NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination
99%Nivolumab Monotherapy (Expansion)
NCT01592370 · Phase 1/2 · registry result, not featured evidence · monotherapy
0%1-5 mCi in 50mg of Antibody
NCT03665155 · Phase 1/2 · registry result, not featured evidence
0%1-5 mCi in 20mg of Antibody
NCT03665155 · Phase 1/2 · registry result, not featured evidence
0%1-5 mCi in 3-50mg of Antibody
NCT03665155 · Phase 1/2 · registry result, not featured evidence
n/a: no completion milestoneg
NCT02990338 · Phase 3 · combination · Multiple Myeloma · phase 3
show 8 more results
n/a: no completion milestone
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
—Phase 1: Isatuximab+Cemiplimab Q2W
NCT03194867 · Phase 1/2 · registry result, not featured evidence · combination
0%Phase 2: Isatuximab
NCT03194867 · Phase 1/2 · registry result, not featured evidence
2.8%Phase 2: Isatuximab + CemiplimabQ2
NCT03194867 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2:Isatuximab + CemiplimabQ4W
NCT03194867 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone20 mg/kg
NCT02812706 · Phase 1/2 · registry result, not featured evidence
—20 mg/kg
NCT02812706 · Phase 1/2 · registry result, not featured evidence
n/a: no completion milestone10 mg/kg
NCT02812706 · Phase 1/2 · registry result, not featured evidence
Discontinued due to AEs
—f
NCT02076009 · Phase 3 · combination · Multiple Myeloma · phase 3
show 54 more results
—
NCT02136134 · Phase 3 · combination · Multiple Myeloma · phase 3
—
NCT03301220 · Phase 3 · combination · Multiple Myeloma · phase 3
—
NCT03901963 · Phase 3 · combination
—16 mg/kg
NCT01985126 · Phase 2
—8 mg/kg
NCT01985126 · Phase 2
33.3%24 mg/kg
NCT00574288 · Phase 2
0%16 mg/kg
NCT00574288 · Phase 2
0%16 mg/kg
NCT00574288 · Phase 2
0%8 mg/kg
NCT00574288 · Phase 2
0%8 mg/kg
NCT00574288 · Phase 2
0%4 mg/kg
NCT00574288 · Phase 2
10%<4 mg/kg
NCT00574288 · Phase 2
5%
NCT05511428 · Phase 4 · registry result, not featured evidence
—
NCT03652064 · Phase 3 · registry result, not featured evidence
—Daratumumab (IV)+Pomalidomide+Dexa
NCT03180736 · Phase 3 · registry result, not featured evidence · combination
—Daratumumab (SC)+Pomalidomide+Dexa
NCT03180736 · Phase 3 · registry result, not featured evidence · combination
—
NCT02252172 · Phase 3 · registry result, not featured evidence · combination
—
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
—
NCT03277105 · Phase 3 · registry result, not featured evidence
—DVTd - Part 1
NCT02541383 · Phase 3 · registry result, not featured evidence · combination
—DVTd-DARA - Part 2
NCT02541383 · Phase 3 · registry result, not featured evidence
—VTd-DARA - Part 2
NCT02541383 · Phase 3 · registry result, not featured evidence
—
NCT03158688 · Phase 3 · registry result, not featured evidence · combination
—
NCT03357952 · Phase 2/3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 2/3
—
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
—
NCT03477539 · Phase 2 · registry result, not featured evidence
—Arm A (Long Intense)
NCT02316106 · Phase 2 · registry result, not featured evidence
—Arm B (Intermediate)
NCT02316106 · Phase 2 · registry result, not featured evidence
—Arm C (Short Intense)
NCT02316106 · Phase 2 · registry result, not featured evidence
—D + Bortezomib + Melphalan + Predn
NCT03412565 · Phase 2 · registry result, not featured evidence · combination
—Daratumumab (D)+Bortezomib+Lenalid
NCT03412565 · Phase 2 · registry result, not featured evidence · combination
—Daratumumab + Carfilzomib + Dexame
NCT03412565 · Phase 2 · registry result, not featured evidence · combination
—Daratumumab + Lenalidomide + Dexam
NCT03412565 · Phase 2 · registry result, not featured evidence · combination
—
NCT03490344 · Phase 2 · registry result, not featured evidence
—
NCT02874742 · Phase 2 · registry result, not featured evidence · combination
—
NCT03450057 · Phase 2 · registry result, not featured evidence · combination
—
NCT03000452 · Phase 2 · registry result, not featured evidence · combination
—
NCT02944565 · Phase 2 · registry result, not featured evidence
0%16 mg/kg
NCT01615029 · Phase 1/2 · registry result, not featured evidence · combination
12.5%16 mg/kg
NCT01615029 · Phase 1/2 · registry result, not featured evidence · combination
75%8mg/kg
NCT01615029 · Phase 1/2 · registry result, not featured evidence · combination
0%4 mg/kg
NCT01615029 · Phase 1/2 · registry result, not featured evidence · combination
33.3%2 mg/kg
NCT01615029 · Phase 1/2 · registry result, not featured evidence · combination
—Nivolumab + Daratumumab Cohort A1
NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination
—Nivolumab + Daratumumab_Cohort A1
NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination
—Nivolumab + Daratumumab_Cohort A2
NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination
—Nivolumab + Daratumumab_Cohort B1
NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination
—Nivolumab + Daratumumab_Cohort B2
NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination
—Nivolumab + Ipilimumab
NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination
—Nivolumab + Lirilumab
NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination
—Nivolumab Monotherapy (Expansion)
NCT01592370 · Phase 1/2 · registry result, not featured evidence · monotherapy
—1-5 mCi in 50mg of Antibody
NCT03665155 · Phase 1/2 · registry result, not featured evidence
—1-5 mCi in 20mg of Antibody
NCT03665155 · Phase 1/2 · registry result, not featured evidence
—1-5 mCi in 3-50mg of Antibody
NCT03665155 · Phase 1/2 · registry result, not featured evidence
14.3%g
NCT02990338 · Phase 3 · combination · Multiple Myeloma · phase 3
show 8 more results
16.2%
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
—Phase 1: Isatuximab+Cemiplimab Q2W
NCT03194867 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2: Isatuximab
NCT03194867 · Phase 1/2 · registry result, not featured evidence
—Phase 2: Isatuximab + CemiplimabQ2
NCT03194867 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2:Isatuximab + CemiplimabQ4W
NCT03194867 · Phase 1/2 · registry result, not featured evidence · combination
40%20 mg/kg
NCT02812706 · Phase 1/2 · registry result, not featured evidence
—20 mg/kg
NCT02812706 · Phase 1/2 · registry result, not featured evidence
0%10 mg/kg
NCT02812706 · Phase 1/2 · registry result, not featured evidence
Serious AEs
72.4%f
NCT02076009 · Phase 3 · combination · Multiple Myeloma · phase 3
show 54 more results
55.1%
NCT02136134 · Phase 3 · combination · Multiple Myeloma · phase 3
29%
NCT03301220 · Phase 3 · combination · Multiple Myeloma · phase 3
30.2%
NCT03901963 · Phase 3 · combination
31.1%16 mg/kg
NCT01985126 · Phase 2
33.3%8 mg/kg
NCT01985126 · Phase 2
66.7%24 mg/kg
NCT00574288 · Phase 2
66.7%16 mg/kg
NCT00574288 · Phase 2
38.1%16 mg/kg
NCT00574288 · Phase 2
33.3%8 mg/kg
NCT00574288 · Phase 2
40%8 mg/kg
NCT00574288 · Phase 2
0%4 mg/kg
NCT00574288 · Phase 2
35%<4 mg/kg
NCT00574288 · Phase 2
15%
NCT05511428 · Phase 4 · registry result, not featured evidence
72.1%
NCT03652064 · Phase 3 · registry result, not featured evidence
42.9%Daratumumab (IV)+Pomalidomide+Dexa
NCT03180736 · Phase 3 · registry result, not featured evidence · combination
54.2%Daratumumab (SC)+Pomalidomide+Dexa
NCT03180736 · Phase 3 · registry result, not featured evidence · combination
79.4%
NCT02252172 · Phase 3 · registry result, not featured evidence · combination
53.8%
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
31.9%
NCT03277105 · Phase 3 · registry result, not featured evidence
49.3%DVTd - Part 1
NCT02541383 · Phase 3 · registry result, not featured evidence · combination
18.8%DVTd-DARA - Part 2
NCT02541383 · Phase 3 · registry result, not featured evidence
27.5%VTd-DARA - Part 2
NCT02541383 · Phase 3 · registry result, not featured evidence
68.5%
NCT03158688 · Phase 3 · registry result, not featured evidence · combination
33.3%
NCT03357952 · Phase 2/3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 2/3
58.3%
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
26.5%
NCT03477539 · Phase 2 · registry result, not featured evidence
48.8%Arm A (Long Intense)
NCT02316106 · Phase 2 · registry result, not featured evidence
34.1%Arm B (Intermediate)
NCT02316106 · Phase 2 · registry result, not featured evidence
10%Arm C (Short Intense)
NCT02316106 · Phase 2 · registry result, not featured evidence
44.8%D + Bortezomib + Melphalan + Predn
NCT03412565 · Phase 2 · registry result, not featured evidence · combination
28.4%Daratumumab (D)+Bortezomib+Lenalid
NCT03412565 · Phase 2 · registry result, not featured evidence · combination
33.3%Daratumumab + Carfilzomib + Dexame
NCT03412565 · Phase 2 · registry result, not featured evidence · combination
56.9%Daratumumab + Lenalidomide + Dexam
NCT03412565 · Phase 2 · registry result, not featured evidence · combination
30%
NCT03490344 · Phase 2 · registry result, not featured evidence
46.5%
NCT02874742 · Phase 2 · registry result, not featured evidence · combination
28.9%
NCT03450057 · Phase 2 · registry result, not featured evidence · combination
38.9%
NCT03000452 · Phase 2 · registry result, not featured evidence · combination
0%
NCT02944565 · Phase 2 · registry result, not featured evidence
66.7%16 mg/kg
NCT01615029 · Phase 1/2 · registry result, not featured evidence · combination
68.8%16 mg/kg
NCT01615029 · Phase 1/2 · registry result, not featured evidence · combination
75%8mg/kg
NCT01615029 · Phase 1/2 · registry result, not featured evidence · combination
66.7%4 mg/kg
NCT01615029 · Phase 1/2 · registry result, not featured evidence · combination
66.7%2 mg/kg
NCT01615029 · Phase 1/2 · registry result, not featured evidence · combination
50%Nivolumab + Daratumumab Cohort A1
NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination
—Nivolumab + Daratumumab_Cohort A1
NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination
100%Nivolumab + Daratumumab_Cohort A2
NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination
36.6%Nivolumab + Daratumumab_Cohort B1
NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination
40.9%Nivolumab + Daratumumab_Cohort B2
NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination
60%Nivolumab + Ipilimumab
NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination
47.2%Nivolumab + Lirilumab
NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination
47.6%Nivolumab Monotherapy (Expansion)
NCT01592370 · Phase 1/2 · registry result, not featured evidence · monotherapy
33.3%1-5 mCi in 50mg of Antibody
NCT03665155 · Phase 1/2 · registry result, not featured evidence
0%1-5 mCi in 20mg of Antibody
NCT03665155 · Phase 1/2 · registry result, not featured evidence
0%1-5 mCi in 3-50mg of Antibody
NCT03665155 · Phase 1/2 · registry result, not featured evidence
73.7%g
NCT02990338 · Phase 3 · combination · Multiple Myeloma · phase 3
show 8 more results
72.9%
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
33.3%Phase 1: Isatuximab+Cemiplimab Q2W
NCT03194867 · Phase 1/2 · registry result, not featured evidence · combination
51.5%Phase 2: Isatuximab
NCT03194867 · Phase 1/2 · registry result, not featured evidence
45.9%Phase 2: Isatuximab + CemiplimabQ2
NCT03194867 · Phase 1/2 · registry result, not featured evidence · combination
60%Phase 2:Isatuximab + CemiplimabQ4W
NCT03194867 · Phase 1/2 · registry result, not featured evidence · combination
40%20 mg/kg
NCT02812706 · Phase 1/2 · registry result, not featured evidence
39.3%20 mg/kg
NCT02812706 · Phase 1/2 · registry result, not featured evidence
33.3%10 mg/kg
NCT02812706 · Phase 1/2 · registry result, not featured evidence
Most frequent reported AEs
f
neutropenia 65.4%
diarrhoea 59.7%
upper respiratory tract infection 43.5%
NCT02076009 · Phase 3 · combination · Multiple Myeloma · phase 3
show 51 more results
thrombocytopenia 59.7%
peripheral sensory neuropathy 50.2%
diarrhoea 36.2%
NCT02136134 · Phase 3 · combination · Multiple Myeloma · phase 3
fatigue 34.2% (placebo 13.3%)
upper respiratory tract infection 30.1% (placebo 7.7%)
arthralgia 26.9% (placebo 17.9%)
NCT03301220 · Phase 3 · combination · Multiple Myeloma · phase 3
neutropenia 64.6%
diarrhoea 61.5%
fatigue 45.8%
NCT03901963 · Phase 3 · combination
16 mg/kg
fatigue 39.6%
anaemia 36.8%
nausea 32.1%
NCT01985126 · Phase 2
8 mg/kg
anaemia 50%
hypertension 44.4%
blood creatinine increased 38.9%
NCT01985126 · Phase 2
24 mg/kg
back pain 33.3%
bronchospasm 33.3%
cough 33.3%
NCT00574288 · Phase 2
16 mg/kg
confusional state 33.3%
cytokine release syndrome 33.3%
eczema asteatotic 33.3%
NCT00574288 · Phase 2
16 mg/kg
fatigue 45.2%
nasopharyngitis 38.1%
back pain 33.3%
NCT00574288 · Phase 2
8 mg/kg
proteinuria 100%
hypertension 66.7%
chest discomfort 33.3%
NCT00574288 · Phase 2
8 mg/kg
fatigue 43.3%
pyrexia 40%
rhinitis allergic 40%
NCT00574288 · Phase 2
4 mg/kg
blood creatine phosphokinase increased 33.3%
cough 33.3%
diarrhoea 33.3%
NCT00574288 · Phase 2
<4 mg/kg
proteinuria 45%
pyrexia 35%
electrocardiogram qt prolonged 25%
NCT00574288 · Phase 2
fatigue 40%
diarrhea 30%
arthralgia 25%
NCT05511428 · Phase 4 · registry result, not featured evidence
diarrhoea 56.3%
peripheral sensory neuropathy 55.8%
neutropenia 54.8%
NCT03652064 · Phase 3 · registry result, not featured evidence
fatigue 57.1%
neutropenia 57.1%
lymphopenia 42.9%
NCT03180736 · Phase 3 · registry result, not featured evidence · combination
neutropenia 72.5%
anaemia 38.7%
thrombocytopenia 33.8%
NCT03180736 · Phase 3 · registry result, not featured evidence · combination
diarrhoea 65.1%
neutropenia 61.5%
fatigue 44.8%
NCT02252172 · Phase 3 · registry result, not featured evidence · combination
neutropenia 50.3%
thrombocytopenia 49.7%
anaemia 31.8%
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
anaemia 27.3%
neutropenia 20%
thrombocytopenia 18.8%
NCT03277105 · Phase 3 · registry result, not featured evidence
peripheral sensory neuropathy 60.6%
constipation 50.6%
asthenia 32.8%
NCT02541383 · Phase 3 · registry result, not featured evidence · combination
bronchitis 40.6%
cough 17%
nasopharyngitis 17%
NCT02541383 · Phase 3 · registry result, not featured evidence
bronchitis 36.5%
cough 19.4%
nasopharyngitis 17.5%
NCT02541383 · Phase 3 · registry result, not featured evidence
thrombocytopenia 38.6%
anaemia 36.7%
hypertension 36.7%
NCT03158688 · Phase 3 · registry result, not featured evidence · combination
neutropenia 44.4%
anaemia 33.3%
fatigue 33.3%
NCT03357952 · Phase 2/3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 2/3
anemia 91.7%
fatigue 91.7%
lymphocyte count decreased 91.7%
NCT01415882 · Phase 2 · registry result, not featured evidence · combination
platelet count decreased 93.9%
anemia 91.8%
neutrophil count decreased 83.7%
NCT03477539 · Phase 2 · registry result, not featured evidence
upper respiratory tract infection 48.8%
fatigue 46.3%
cough 43.9%
NCT02316106 · Phase 2 · registry result, not featured evidence
fatigue 61%
arthralgia 46.3%
cough 36.6%
NCT02316106 · Phase 2 · registry result, not featured evidence
headache 32.5%
cough 27.5%
fatigue 22.5%
NCT02316106 · Phase 2 · registry result, not featured evidence
thrombocytopenia 56.7%
anaemia 44.8%
constipation 44.8%
NCT03412565 · Phase 2 · registry result, not featured evidence · combination
peripheral sensory neuropathy 41.8%
constipation 38.8%
neutropenia 37.3%
NCT03412565 · Phase 2 · registry result, not featured evidence · combination
thrombocytopenia 51.5%
anaemia 37.9%
hypertension 34.8%
NCT03412565 · Phase 2 · registry result, not featured evidence · combination
neutropenia 67.7%
diarrhoea 49.2%
anaemia 40%
NCT03412565 · Phase 2 · registry result, not featured evidence · combination
fatigue 71.7%
upper respiratory tract infection 67.7%
diarrhoea 65.7%
NCT02874742 · Phase 2 · registry result, not featured evidence · combination
anaemia 28.9%
fatigue 23.7%
hypocalcaemia 18.4%
NCT03450057 · Phase 2 · registry result, not featured evidence · combination
anaemia 66.7%
fatigue 50%
thrombocytopenia 38.9%
NCT03000452 · Phase 2 · registry result, not featured evidence · combination
16 mg/kg
muscle spasms 100%
oedema peripheral 100%
bronchitis 66.7%
NCT01615029 · Phase 1/2 · registry result, not featured evidence · combination
16 mg/kg
neutropenia 90.6%
diarrhoea 56.3%
cough 50%
NCT01615029 · Phase 1/2 · registry result, not featured evidence · combination
8mg/kg
fatigue 100%
neutropenia 100%
diarrhoea 75%
NCT01615029 · Phase 1/2 · registry result, not featured evidence · combination
4 mg/kg
cataract 100%
constipation 100%
diarrhoea 100%
NCT01615029 · Phase 1/2 · registry result, not featured evidence · combination
2 mg/kg
constipation 100%
fatigue 100%
neutropenia 100%
NCT01615029 · Phase 1/2 · registry result, not featured evidence · combination
anaemia 50%
arthralgia 50%
cough 50%
NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination
anaemia 80%
diarrhoea 80%
hypomagnesaemia 80%
NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination
anaemia 24.4%
infusion related reaction 24.4%
neutropenia 22%
NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination
anaemia 18.2%
diarrhoea 18.2%
infusion related reaction 18.2%
NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 46.2%
pyrexia 38.5%
cough 33.8%
NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 41.7%
diarrhoea 29.2%
anaemia 25%
NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 43.8%
cough 27.6%
diarrhoea 26.7%
NCT01592370 · Phase 1/2 · registry result, not featured evidence · monotherapy
1-5 mCi in 50mg of Antibody
lymphocyte count decreased 66.7%
neutrophil count decreased 66.7%
white blood cell decreased 66.7%
NCT03665155 · Phase 1/2 · registry result, not featured evidence
1-5 mCi in 20mg of Antibody
lymphocyte count decreased 57.1%
neutrophil count decreased 28.6%
white blood cell decreased 28.6%
NCT03665155 · Phase 1/2 · registry result, not featured evidence
1-5 mCi in 3-50mg of Antibody
anemia 0%
aspartate aminotransferase increased 0%
blood bilirubin increased 0%
NCT03665155 · Phase 1/2 · registry result, not featured evidence
g
neutropenia 50.7%
upper respiratory tract infection 34.9%
infusion related reaction 34.2%
NCT02990338 · Phase 3 · combination · Multiple Myeloma · phase 3
show 8 more results
infusion related reaction 45.2%
upper respiratory tract infection 41.2%
diarrhoea 40.7%
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
infusion related reaction 66.7%
back pain 33.3%
chills 33.3%
NCT03194867 · Phase 1/2 · registry result, not featured evidence · combination
infusion related reaction 54.5%
diarrhoea 18.2%
arthralgia 15.2%
NCT03194867 · Phase 1/2 · registry result, not featured evidence
infusion related reaction 40.5%
fatigue 21.6%
back pain 18.9%
NCT03194867 · Phase 1/2 · registry result, not featured evidence · combination
infusion related reaction 42.9%
diarrhoea 20%
upper respiratory tract infection 20%
NCT03194867 · Phase 1/2 · registry result, not featured evidence · combination
20 mg/kg
vomiting 40%
anaemia 20%
fatigue 20%
NCT02812706 · Phase 1/2 · registry result, not featured evidence
20 mg/kg
infusion related reaction 42.9%
nasopharyngitis 21.4%
pyrexia 21.4%
NCT02812706 · Phase 1/2 · registry result, not featured evidence
10 mg/kg
infusion related reaction 66.7%
nasopharyngitis 66.7%
back pain 33.3%
NCT02812706 · Phase 1/2 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bTrial phases differ: Phase 2 versus Phase 1/2.
  3. cPopulation comparability has not been reviewed for both studies.
  4. dThe assessment timepoint is not available for both results.
  5. eTreatment context has not been resolved for both arms.
  6. fPopulation comparability has not been reviewed for 51 of these studies.
  7. gPopulation comparability has not been reviewed for 7 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Daratumumab

MRD Negative 13.5% (n=251) vs 2.8% (n=247) Bortezomib + Dexamethasone
responder rate · % of participants
NCT02136134 · Phase 3 · combination · Multiple Myeloma · phase 3
show 5 more results
53.3% (n=197) vs 35.4% (n=198) Bortezomib-lenalidomide-dexamethasone (VRd)
NCT03652064 · Phase 3 · registry result, not featured evidence
60.9% (n=197) vs 39.4% (n=198) Bortezomib-lenalidomide-dexamethasone (VRd)
NCT03652064 · Phase 3 · registry result, not featured evidence
32.1% (n=368) vs 11.1% (n=369) Lenalidomide + Dexamethasone
NCT02252172 · Phase 3 · registry result, not featured evidence · combination
28.3% (n=350) vs 7% (n=356) Velcade, Melphalan and Prednisone
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
18.3% (n=312) vs 5.2% (n=154) Carfilzomib and Dexamethasone @ 52wk
NCT03158688 · Phase 3 · registry result, not featured evidence · combination
MRD Conversion 50.5% (n=99) vs 18.8% (n=101) Lenalidomide @ 52wk
responder rate · % of participants
NCT03901963 · Phase 3 · combination
Time to First Response 1.9 months24 mg/kg
time to event · months
No placebo or comparator arm
Time to first response
NCT00574288 · Phase 2
show 10 more results
8.4 months16 mg/kg
Time to first response
NCT00574288 · Phase 2
1.33 months16 mg/kg
Time to first response
NCT00574288 · Phase 2
2.25 months16 mg/kg
Time to first response
NCT01615029 · Phase 1/2 · registry result, not featured evidence · combination
0.99 months16 mg/kg
Time to first response
NCT01615029 · Phase 1/2 · registry result, not featured evidence · combination
NA months8 mg/kg
Time to first response
NCT00574288 · Phase 2
1.36 months8 mg/kg
Time to first response
NCT00574288 · Phase 2
1.02 months8 mg/kg
Time to first response
NCT01615029 · Phase 1/2 · registry result, not featured evidence · combination
NA months4 mg/kg
Time to first response
NCT00574288 · Phase 2
1.02 months4 mg/kg
Time to first response
NCT01615029 · Phase 1/2 · registry result, not featured evidence · combination
0.99 months2 mg/kg
Time to first response
NCT01615029 · Phase 1/2 · registry result, not featured evidence · combination
Time to Best Response 1.9 months24 mg/kg
time to event · months
No placebo or comparator arm
Time to best response
NCT00574288 · Phase 2
show 10 more results
8.4 months16 mg/kg
Time to best response
NCT00574288 · Phase 2
2.46 months16 mg/kg
Time to best response
NCT00574288 · Phase 2
16.72 months16 mg/kg
Time to best response
NCT01615029 · Phase 1/2 · registry result, not featured evidence · combination
6.95 months16 mg/kg
Time to best response
NCT01615029 · Phase 1/2 · registry result, not featured evidence · combination
NA months8 mg/kg
Time to best response
NCT00574288 · Phase 2
1.36 months8 mg/kg
Time to best response
NCT00574288 · Phase 2
8.41 months8 mg/kg
Time to best response
NCT01615029 · Phase 1/2 · registry result, not featured evidence · combination
NA months4 mg/kg
Time to best response
NCT00574288 · Phase 2
13.17 months4 mg/kg
Time to best response
NCT01615029 · Phase 1/2 · registry result, not featured evidence · combination
1.9 months2 mg/kg
Time to best response
NCT01615029 · Phase 1/2 · registry result, not featured evidence · combination
Time to VGPR or Better 0.49 months16 mg/kg
time to event · months
No placebo or comparator arm
Time to VGPR or better response
NCT00574288 · Phase 2
Treatment Satisfaction 87.2 score @ 0wk
absolute value · score
No placebo or comparator arm
NCT05511428 · Phase 4 · registry result, not featured evidence
show 7 more results
87.4 score @ 4.14wk
NCT05511428 · Phase 4 · registry result, not featured evidence
89.3 score @ 8.14wk
NCT05511428 · Phase 4 · registry result, not featured evidence
86.1 score @ 12.14wk
NCT05511428 · Phase 4 · registry result, not featured evidence
88.2 score @ 16.14wk
NCT05511428 · Phase 4 · registry result, not featured evidence
85.7 score @ 20.14wk
NCT05511428 · Phase 4 · registry result, not featured evidence
89.7 score @ 24.14wk
NCT05511428 · Phase 4 · registry result, not featured evidence
90.1 score @ 28.14wk
NCT05511428 · Phase 4 · registry result, not featured evidence
EORTC QLQ-C30 GHS 64.2 score @ 0wk
absolute value · score
No placebo or comparator arm
NCT05511428 · Phase 4 · registry result, not featured evidence
show 7 more results
69.3 score @ 4.14wk
NCT05511428 · Phase 4 · registry result, not featured evidence
64.4 score @ 8.14wk
NCT05511428 · Phase 4 · registry result, not featured evidence
65.8 score @ 12.14wk
NCT05511428 · Phase 4 · registry result, not featured evidence
57.5 score @ 16.14wk
NCT05511428 · Phase 4 · registry result, not featured evidence
69.1 score @ 20.14wk
NCT05511428 · Phase 4 · registry result, not featured evidence
69.3 score @ 24.14wk
NCT05511428 · Phase 4 · registry result, not featured evidence
62.3 score @ 28.14wk
NCT05511428 · Phase 4 · registry result, not featured evidence
CR/sCR 51.1% (n=368) vs 30.1% (n=369) Lenalidomide + Dexamethasone
responder rate · % of participants
NCT02252172 · Phase 3 · registry result, not featured evidence · combination
show 2 more results
42.6% (n=350) vs 24.4% (n=356) Velcade, Melphalan and Prednisone
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
4.6% (n=263) vs 5.4% (n=259) Daratumumab IV
NCT03277105 · Phase 3 · registry result, not featured evidence
Stringent Complete 35.6% (n=368) vs 15.7% (n=369) Lenalidomide + Dexamethasone
responder rate · % of participants
NCT02252172 · Phase 3 · registry result, not featured evidence · combination
show 2 more results
18% (n=350) vs 7% (n=356) Velcade, Melphalan and Prednisone
NCT02195479 · Phase 3 · registry result, not featured evidence · combination
42.4% (n=99) vs 32% (n=97) Lenalidomide+Bortezomib+Dexamethasone
NCT02874742 · Phase 2 · registry result, not featured evidence · combination
Time to First Response 1.05 vs 1.05 Lenalidomide + Dexamethasone months
time to event · months
Time to first response
NCT02252172 · Phase 3 · registry result, not featured evidence · combination
Time to VGPR or Better 3.01 vs 4.7 Lenalidomide + Dexamethasone months
time to event · months
Time to VGPR or better
NCT02252172 · Phase 3 · registry result, not featured evidence · combination
Time to Complete Response 10.66 vs 13.17 Lenalidomide + Dexamethasone months
time to event · months
Time to CR or better
NCT02252172 · Phase 3 · registry result, not featured evidence · combination

+ 92 further endpoints in the CSV export.

Isatuximab

Clinical Benefit 66.9% (n=154) vs 46.4% (n=153) Pomalidomide + Dexamethasone
responder rate · % of participants
NCT02990338 · Phase 3 · combination · Multiple Myeloma · phase 3
VGPR or Better With MRD Negativity 29.6% (n=179) vs 13% (n=123) Carfilzomib + Dexamethasone
responder rate · % of participants
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
show 1 more result
33.5% (n=179) vs 13.8% (n=123) Carfilzomib + Dexamethasone
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
Complete Renal 52% (n=25) vs 30.8% (n=13) Carfilzomib + Dexamethasone
responder rate · % of participants
CR Renal
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3 · converted to % from 13 Participants as posted

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Daratumumab's landscape · Isatuximab's landscape